BioArctic AB (publ) (BIOA-B.ST)
SEK 168.1
(1.2%)
SEK 168.1
(1.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 252.64 Million SEK | 2626.73% |
| 2022 | -10.15 Million SEK | 92.73% |
| 2021 | -139.72 Million SEK | -69.74% |
| 2020 | -82.31 Million SEK | -173.15% |
| 2019 | 112.53 Million SEK | -76.98% |
| 2018 | 488.79 Million SEK | 2433.4% |
| 2017 | 19.29 Million SEK | -74.15% |
| 2016 | 74.63 Million SEK | 1440.69% |
| 2015 | 4.84 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -75.43 Million SEK | -3.75% |
| 2024 Q1 | -73.09 Million SEK | 8.23% |
| 2023 Q1 | 300.58 Million SEK | 595.54% |
| 2023 Q4 | -79.65 Million SEK | -160.8% |
| 2023 Q2 | -100.86 Million SEK | -133.56% |
| 2023 Q3 | 131.01 Million SEK | 229.88% |
| 2023 FY | 256.69 Million SEK | 2626.73% |
| 2022 Q3 | 133.03 Million SEK | 390.8% |
| 2022 FY | -10.15 Million SEK | 92.73% |
| 2022 Q4 | -60.65 Million SEK | -145.6% |
| 2022 Q2 | -45.74 Million SEK | -3.8% |
| 2022 Q1 | -44.07 Million SEK | -11.97% |
| 2021 Q2 | -33.81 Million SEK | -16.02% |
| 2021 Q1 | -29.14 Million SEK | 3.37% |
| 2021 Q4 | -39.35 Million SEK | -5.21% |
| 2021 Q3 | -37.4 Million SEK | -10.64% |
| 2021 FY | -139.72 Million SEK | -69.74% |
| 2020 Q3 | -20.7 Million SEK | 45.42% |
| 2020 Q4 | -30.15 Million SEK | -45.64% |
| 2020 FY | -82.31 Million SEK | -173.15% |
| 2020 Q1 | 3.79 Million SEK | 118.0% |
| 2020 Q2 | -37.94 Million SEK | -1100.0% |
| 2019 FY | 112.53 Million SEK | -76.98% |
| 2019 Q4 | -21.07 Million SEK | -100.51% |
| 2019 Q3 | -10.51 Million SEK | -108.29% |
| 2019 Q2 | 126.78 Million SEK | 631.39% |
| 2019 Q1 | 17.33 Million SEK | -95.97% |
| 2018 FY | 488.79 Million SEK | 2433.4% |
| 2018 Q2 | 6.44 Million SEK | -65.9% |
| 2018 Q4 | 430.32 Million SEK | 1199.08% |
| 2018 Q1 | 18.9 Million SEK | 28.31% |
| 2018 Q3 | 33.12 Million SEK | 413.88% |
| 2017 Q3 | 619 Thousand SEK | -74.99% |
| 2017 FY | 19.29 Million SEK | -74.15% |
| 2017 Q4 | 14.73 Million SEK | 2279.97% |
| 2017 Q2 | 2.47 Million SEK | 68.48% |
| 2017 Q1 | 1.46 Million SEK | -98.49% |
| 2016 Q1 | -6.25 Million SEK | 0.0% |
| 2016 FY | 74.63 Million SEK | 1440.69% |
| 2016 Q4 | 97.33 Million SEK | 1054.81% |
| 2016 Q3 | -10.19 Million SEK | 9.33% |
| 2016 Q2 | -11.24 Million SEK | -79.77% |
| 2015 FY | 4.84 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| 2cureX AB (publ) | -36.36 Million SEK | 794.772% |
| Abliva AB (publ) | -96.54 Million SEK | 361.673% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 327.78% |
| AcouSort AB (publ) | -17.48 Million SEK | 1544.73% |
| Active Biotech AB (publ) | -46.48 Million SEK | 643.499% |
| Alzinova AB (publ) | -16.52 Million SEK | 1629.113% |
| Amniotics AB (publ) | -29.07 Million SEK | 968.985% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 671.894% |
| Aptahem AB (publ) | -10.1 Million SEK | 2600.208% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 1825.683% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 201.469% |
| BioInvent International AB (publ) | -369.94 Million SEK | 168.292% |
| Biosergen AB | -27.26 Million SEK | 1026.609% |
| Biovica International AB (publ) | -126.07 Million SEK | 300.392% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 555.889% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 165.724% |
| Camurus AB (publ) | 532.35 Million SEK | 52.543% |
| Cantargia AB (publ) | -290.01 Million SEK | 187.112% |
| Corline Biomedical AB | -1.78 Million SEK | 14229.754% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 1354.481% |
| CombiGene AB (publ) | -36.3 Million SEK | 795.879% |
| Cyxone AB (publ) | -21.66 Million SEK | 1266.336% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 2284.333% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 272.372% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 177.783% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 1577.749% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 338.418% |
| Fluicell AB (publ) | -26.87 Million SEK | 1039.916% |
| Genovis AB (publ.) | 54.22 Million SEK | -365.919% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 319.548% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 132.041% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 287.673% |
| Mendus AB (publ) | -100.65 Million SEK | 351.008% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 239.762% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 706.098% |
| I-Tech AB | 24.43 Million SEK | -933.927% |
| Intervacc AB (publ) | -93.57 Million SEK | 369.975% |
| Kancera AB (publ) | -65.04 Million SEK | 488.426% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 7307.989% |
| LIDDS AB (publ) | -40.67 Million SEK | 721.134% |
| Lipum AB (publ) | -37.25 Million SEK | 778.155% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 2142.195% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | -1302.854% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 1640.394% |
| Nanologica AB (publ) | -69.96 Million SEK | 461.105% |
| NextCell Pharma AB | -43.17 Million SEK | 685.192% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 199.682% |
| OncoZenge AB (publ) | -15.9 Million SEK | 1688.731% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 4051.668% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 1728.675% |
| Saniona AB (publ) | -81.06 Million SEK | 411.651% |
| Simris Alg AB (publ) | -36.63 Million SEK | 789.614% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 694.377% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 29998.225% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 1154.676% |
| SynAct Pharma AB | -224.49 Million SEK | 212.537% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 178.58% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 181.385% |
| Xintela AB (publ) | -57.23 Million SEK | 541.385% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 239.762% |
| Ziccum AB (publ) | -21.56 Million SEK | 1271.8% |